West Virginia Clinical Trials Report — May 2026

For West Virginians considering participation in clinical research, May 2026 brings a critical opportunity to act, particularly for those interested in trials nearing their enrollment deadlines. Across the state, 20 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 2 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, gastrointestinal issues, and other health challenges are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Irritable bowel syndrome with constipation (IBS-C)
• Stage IV lung cancer AJCC v8
• Anatomic stage II breast cancer AJCC v8
• Anterior cruciate ligament rupture
• Cancer harboring BRAF alterations
• Cardiovascular diseases
• Chronic granulomatous disease (CGD)
• Cervical carcinoma
• Endocrine system diseases
• Exophthalmos

These closing trials represent diverse areas of medical inquiry, from specific cancer types to orthopedic injuries and rare genetic conditions. If you or someone you know has been diagnosed with one of these conditions, now is the time to investigate whether a clinical trial could be a suitable option.

A Significant New Research Opportunity in Morgantown

This month, West Virginia welcomes a notable new Phase 3 drug trial, offering a substantial opportunity for individuals living with heart failure and obesity. This single new trial, sponsored by a major pharmaceutical company, highlights a significant commitment to addressing complex health challenges.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, with sites in West Virginia. The study's primary goal is to evaluate the safety and effect of the investigational drug NNC0487-0111 in individuals diagnosed with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) who also have excess body weight. This research is crucial for potentially identifying new treatment avenues for these interconnected conditions.

This new trial is exclusively focused on drug intervention and is sponsored by industry, reflecting a trend of pharmaceutical companies investing in advanced-stage research within the state. It is open to older adults, ensuring that senior populations have the opportunity to contribute to this important medical advancement.

West Virginia's Broader Research Landscape

While only 1 new trial opened this month – a decrease compared to the 2 new trials in April and 3 in March 2026 – West Virginia continues to offer a broad array of research opportunities. Currently, there are 329 clinical trials actively recruiting participants across 23 cities and 159 research sites throughout the state.

The new trial this month is located in Morgantown, a key hub for medical research in West Virginia. This geographic distribution ensures that residents in different parts of the state have access to various research opportunities, from major metropolitan areas to more localized communities. The presence of 159 research sites indicates a widespread infrastructure dedicated to clinical investigation.

For individuals without a specific medical condition, opportunities to contribute to medical science remain available. While the single new trial this month does not accept healthy volunteers, there are still 24 total clinical trials currently recruiting healthy participants statewide. These studies play a vital role in understanding normal bodily functions, testing new diagnostic tools, and establishing baseline data for future treatments.

Participation in clinical trials is open to a wide range of individuals. Of the new trials launched this month, 1 includes older adults, ensuring that senior populations have ample opportunity to contribute to medical science. There are no new trials specifically for children, or those exclusively for females or males this month.

As we move forward, the focus will remain on the ongoing enrollment in these significant trials, including the new Phase 3 study from Novo Nordisk A/S. Researchers across West Virginia will continue to seek participants for a diverse range of studies, aiming to address pressing health challenges and advance medical knowledge for the benefit of all.